



## **Elpiscience to Present at BIO-Europe Spring 2023 in Basel**

Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a clinical-stage biopharmaceutical company dedicated to developing life-changing immuno-oncology therapies for cancer patients worldwide, today announced that it will be presenting in person at the 17th annual BIO-Europe Spring taking place March 20-22, 2023 in Basel, Switzerland.

Elpiscience has been focused on removing immunosuppressive factors in the tumor microenvironment, by targeting the adenosine pathway and myeloid checkpoints. Darren Ji, Co-founder and CEO of Elpiscience, will present the company’s core pipeline programs including its Phase 1 ES014, a first-in-class anti-CD39/TGF- $\beta$  bispecific antibody that is expected of having single agent anti-tumor activity, a highly differentiated anti-LILRB2 antibody ES009 that effectively reprogram macrophage from M2 to M1, and a pan-acting anti-SIPR $\alpha$  antibody ES004 with a larger population coverage.

Darren Ji will also join a panel to discuss the involving APAC partnering paradigms on March 21, 2023 during the event.

### **Presentation schedule:**

**Date and Time:** March 20th, 13:00-13:15 (CET)

**Presenter:** Darren Ji, Co-Founder and CEO of Elpiscience

**Venue:** Room 2, Messe Basel, Basel, Switzerland

### **Panel schedule:**

**Panel Discussion:** APAC partnering: where are we and where does the future lie?

**Panelist:** Darren Ji, Co-Founder and CEO of Elpiscience



**Date and Time:** March 21st, 10:30 - 11:15 (CET)

**Venue:** Room 1, Messe Basel, Basel, Switzerland

**About Elpiscience:**

Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. It has four molecules in clinical trials, including ES104, ES101, ES102, and ES002. Founded and managed by a team of biopharma industry leaders and scientists, Elpiscience is backed by renowned investors including, Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management.

Elpiscience endeavors to advance at least one innovative molecule into the clinic each year to benefit cancer patients worldwide.

Learn more at [elpiscience.com](http://elpiscience.com)

**Investor inquiries:**

John Craighead, Ph.D.  
[IR@elpiscience.com](mailto:IR@elpiscience.com)

**Media inquiries:**

Candy Zhao  
[PR@elpiscience.com](mailto:PR@elpiscience.com)